Sweeten the deal: Glycopolymer-based engineering to modulate autoreactive T cell responses
- PMID: 37865097
- PMCID: PMC10638033
- DOI: 10.1016/j.ymthe.2023.10.014
Sweeten the deal: Glycopolymer-based engineering to modulate autoreactive T cell responses
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses.Nat Biomed Eng. 2023 Sep;7(9):1142-1155. doi: 10.1038/s41551-023-01086-2. Epub 2023 Sep 7. Nat Biomed Eng. 2023. PMID: 37679570
References
-
- Tremain A.C., Wallace R.P., Lorentz K.M., Thornley T.B., Antane J.T., Raczy M.R., Reda J.W., Alpar A.T., Slezak A.J., Watkins E.A., et al. Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses. Nat. Biomed. Eng. 2023;7:1142–1155. doi: 10.1038/s41551-023-01086-2. - DOI - PubMed
-
- Keeler G.D., Kumar S., Palaschak B., Silverberg E.L., Markusic D.M., Jones N.T., Hoffman B.E. Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis. Mol. Ther. 2018;26:173–183. doi: 10.1016/j.ymthe.2017.09.001. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
